• Explore /
  • Poster
  • / Phase II study of pembrolizumab after chemoradiotherapy (CRT) as adjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients at high risk of recurrence following preoperative CRT plus surgery.

Phase II study of pembrolizumab after chemoradiotherapy (CRT) as adjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients at high risk of recurrence following preoperative CRT plus surgery.

Abstract Poster

Authors

null

Chih-Hung Hsu

National Taiwan University Cancer Center, Taipei City, Taiwan

Chih-Hung Hsu , Jhe-Cyuan Guo , Ta-Chen Huang , Hung-Yang Kuo , Chia-Chi Lin , Feng-Ming Hsu , Jason C. Cheng , Pei-Ming Huang , Jang-Ming Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03322267

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS259)

DOI

10.1200/JCO.2021.39.3_suppl.TPS259

Abstract #

TPS259

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jhe-Cyuan Guo

First Author: Satoru Matsuda

First Author: Toshiharu Hirose

First Author: Manabu Muto